论文部分内容阅读
目的 :观察乙肝康胶囊对实验性肝损伤的保护作用及机理。方法 :用CCl4 造成大鼠慢性肝损伤模型 ;D 氨基半乳糖造成小鼠急性肝损伤模型 ;肝悬液和Freund佐剂造成豚鼠免疫性肝损伤模型 ,乙肝康胶囊分高低剂量组ig治疗。结果 :本品 3.7和 7.4g·kg-1剂量组均能使CCl4 所致大鼠慢性肝损伤血清中总蛋白TP、A/G、HA、AST、ALT值恢复正常。乙肝康的 11.1g·kg-1剂量组能使D -氨基半乳糖造成的小鼠急性肝损伤血清中AST和ALT值降低。乙肝康 5 .6g·kg-1剂量组能降低豚鼠免疫性肝损伤模型血清中ALT与AST水平。肝组织病理学显示 :乙肝康胶囊均能减轻肝细胞的病理损伤。结论 :乙肝康胶囊对这 3种肝损伤模型有明显的保护和修复作用
Objective: To observe the protective effect of Yigankang capsule on experimental hepatic injury and its mechanism. METHODS: Rat model of chronic liver injury was induced with CCl4, D-galactosamine-induced acute liver injury model, Liver suspension and Freund adjuvant were used to induce guinea pig model of immune liver injury, and Yigankang capsule was divided into high-dose group and low-dose group. RESULTS: Both 3.7 and 7.4 g·kg-1 doses of this product could restore normal serum total protein TP, A/G, HA, AST, and ALT values in chronic liver injury induced by CCl4 in rats. Yigankang’s 11.1g·kg-1 dose group can reduce the serum AST and ALT levels caused by D-galactosamine in acute liver injury in mice. Yigankang 5.6g·kg-1 dose group can reduce the serum ALT and AST levels in the guinea pig model of immune liver injury. Liver histopathology showed that: Yigankang capsules can reduce the pathological damage of liver cells. Conclusion : Yigankang capsule has obvious protection and repair effect on these three liver injury models